4.35
price down icon1.81%   -0.08
after-market After Hours: 4.35
loading
Karyopharm Therapeutics Inc stock is traded at $4.35, with a volume of 48,391. It is down -1.81% in the last 24 hours and down -3.12% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$4.43
Open:
$4.42
24h Volume:
48,391
Relative Volume:
0.42
Market Cap:
$37.58M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-3.4252
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
+12.99%
1M Performance:
-3.12%
6M Performance:
-58.57%
1Y Performance:
-69.80%
1-Day Range:
Value
$4.35
$4.60
1-Week Range:
Value
$3.85
$4.91
52-Week Range:
Value
$3.51
$16.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
Name
Karyopharm Therapeutics Inc
Name
Phone
617-658-0600
Name
Address
85 WELLS AVENUE, NEWTON, MA
Name
Employee
279
Name
Twitter
@Karyopharm
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
4.35 41.99M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 122.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 31.91B 3.81B -644.79M -669.77M -6.24

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-16-25 Downgrade H.C. Wainwright Buy → Neutral
Jul-11-25 Resumed H.C. Wainwright Buy
Jan-19-23 Initiated Piper Sandler Overweight
Nov-04-22 Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-09-22 Upgrade JP Morgan Underweight → Neutral
Nov-19-21 Resumed Morgan Stanley Equal-Weight
Aug-06-21 Downgrade JP Morgan Overweight → Neutral
Aug-06-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Aug-06-21 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-02-20 Initiated Morgan Stanley Overweight
Mar-04-20 Initiated Barclays Overweight
Jan-17-20 Downgrade Wedbush Outperform → Neutral
Jul-23-19 Upgrade JP Morgan Neutral → Overweight
Jul-05-19 Reiterated H.C. Wainwright Buy
Jul-05-19 Reiterated Robert W. Baird Outperform
Mar-01-19 Downgrade JP Morgan Overweight → Neutral
Feb-28-19 Reiterated BofA/Merrill Underperform
Feb-27-19 Downgrade BofA/Merrill Neutral → Underperform
Jan-03-19 Upgrade BofA/Merrill Underperform → Neutral
Dec-03-18 Initiated B. Riley FBR Buy
Nov-09-18 Upgrade Wedbush Neutral → Outperform
May-24-18 Downgrade Wedbush Outperform → Neutral
Apr-02-18 Resumed Leerink Partners Outperform
Nov-15-17 Resumed H.C. Wainwright Buy
Sep-15-17 Initiated RBC Capital Mkts Outperform
Sep-08-16 Reiterated H.C. Wainwright Buy
Aug-30-16 Upgrade Jefferies Hold → Buy
Aug-18-16 Initiated H.C. Wainwright Buy
Jun-28-16 Initiated Robert W. Baird Outperform
View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

pulisher
02:33 AM

What drives Karyopharm Therapeutics Inc. stock priceConsistently high returns - PrintWeekIndia

02:33 AM
pulisher
06:23 AM

Karyopharm Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - PrintWeekIndia

06:23 AM
pulisher
04:35 AM

What analysts say about Karyopharm Therapeutics Inc. stockUnprecedented market success - Autocar Professional

04:35 AM
pulisher
Jul 24, 2025

How high can Karyopharm Therapeutics Inc. stock price go in 2025High-yield market plays - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

Triple Refractory Multiple Myeloma Market Forecast 2032: - openPR.com

Jul 23, 2025
pulisher
Jul 23, 2025

Is Karyopharm Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 22, 2025
pulisher
Jul 22, 2025

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress

Jul 22, 2025
pulisher
Jul 18, 2025

Will Karyopharm Therapeutics Inc. stock split in the near futureHigh Return Intraday Picks - Newser

Jul 18, 2025
pulisher
Jul 17, 2025

HC Wainwright & Co. Downgrades Karyopharm Therapeutics (KPTI) - MSN

Jul 17, 2025
pulisher
Jul 16, 2025

H.C. Wainwright downgrades Karyopharm stock to Neutral amid financial concerns - Investing.com Canada

Jul 16, 2025
pulisher
Jul 15, 2025

Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

How Karyopharm Therapeutics Inc. stock performs during market volatilityTop Performing Low Risk Stocks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Karyopharm Therapeutics Inc. stock price move sharplyROI Driven Alerts - beatles.ru

Jul 15, 2025
pulisher
Jul 15, 2025

Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionFree Stock Market Expert Consultation - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Newton biotech cuts over 50 jobs, and other biotech news - The Business Journals

Jul 15, 2025
pulisher
Jul 13, 2025

HC Wainwright Initiates Coverage on Karyopharm Therapeutics (NASDAQ:KPTI) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Karyopharm Therapeutics: A Liquidity Crossroads with Little Room to Pivot - AInvest

Jul 12, 2025
pulisher
Jul 11, 2025

Karyopharm stock tumbles after disclosing failed financing talks By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN

Jul 11, 2025
pulisher
Jul 11, 2025

Karyopharm's Freefall: What's Driving the Collapse? - AInvest

Jul 11, 2025

Karyopharm Therapeutics Inc Stock (KPTI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Karyopharm Therapeutics Inc Stock (KPTI) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Paulson Richard A.
President and CEO
May 06 '25
Sale
7.12
236
1,680
82,503
Rangwala Reshma
EVP & Chief Medical Officer
Apr 23 '25
Sale
6.17
419
2,585
28,853
Paulson Richard A.
President and CEO
Apr 04 '25
Sale
3.74
245
916
82,739
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Mar 04 '25
Sale
6.29
3,445
21,669
34,314
Paulson Richard A.
President and CEO
Mar 04 '25
Sale
6.29
11,694
73,555
82,984
Rangwala Reshma
EVP & Chief Medical Officer
Mar 04 '25
Sale
6.29
3,587
22,562
29,272
Poulton Stuart
EVP, Chief Development Officer
Mar 04 '25
Sale
6.29
3,548
22,317
27,414
Mano Michael
SVP, General Counsel&Secretary
Mar 04 '25
Sale
6.29
2,793
17,568
21,047
Poulton Stuart
EVP, Chief Development Officer
Feb 18 '25
Sale
0.63
5,914
3,726
320,714
Paulson Richard A.
President and CEO
Feb 04 '25
Sale
0.65
4,099
2,664
1,120,158
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):